4D Molecular Therapeutics announces shareholder vote results; all director nominees elected and auditor ratified

4D Molecular Therapeutics, Inc.

At May 23 annual meeting, 27,970,603 of 33,235,726 outstanding shares voted, representing 84.1% quorum.
Class III directors elected: Nancy Miller-Rich (25,544,878 for, 648,302 withheld), John F. Milligan (26,011,514 for, 181,666 withheld), Shawn Cline Tomasello (20,935,207 for, 5,257,973 withheld).
Ratification of PricewaterhouseCoopers LLP as auditor for FY2023 passed with 27,957,650 for, 6,435 against, 6,518 abstain.
Broker non-votes on director election totaled 1,777,423 shares.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

4D Molecular Therapeutics, Inc. shareholders approved Election of Class III director nominees at the 2023-05-23 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-23

Exact text from the filing

Proposal 1. The Company’s stockholders elected by a majority of votes cast the Class III director nominees below to the Company’s Board of Directors to hold office until the 2026 Annual Meeting of Stockholders or until their successors are elected.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

4D Molecular Therapeutics, Inc. shareholders approved Ratification of selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-23 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-23

Exact text from the filing

Proposal 2. The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.

View on SEC.gov

Browse all shareholder votes →

4D Molecular Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-154338

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.